Evaluation of the effects of single‐nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses

thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol 2008; 18: 164–71. Doi:10.1111/j.1750-3639.2007.00108.x. 4 Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro Oncol 2012; 14(Suppl 4): iv73–80. Doi:10.1093/neuonc/nos197. 5 Sartori MT, Della Puppa A, Ballin A, Saggiorato G, Bernardi D, Padoan A, Scienza R, d’Avella D, Cella G. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol 2011; 104: 225–31. Doi:10.1007/s11060-010-0462-8. 6 Thaler J, Preusser M, Ay C, Kaider A, Marosi C, Zielinski C, Pabinger I, Hainfellner JA. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res 2013; 131: 162–5. doi:10.1016/j.thromres.2012.09.020 [Epub ahead of print]. 7 Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105: 1734–41. Doi:10.1182/blood-2004-05-2042. 8 Rak J, Yu JL, Luyendyk J, Mackman N. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006; 66: 10643–6. Doi:10.1158/0008-5472.CAN-06-2350. 9 Milsom CC YJ, Mackman N, Micallef J, Anderson GM, Guha A, Rak J. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res 2008; 68: 10068–76. 10 Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, van Meir EG, Mackman N, Brat DJ. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 2009; 69: 2540–9. Doi:10.1158/00085472.CAN-08-1547. 11 Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood 2010; 116: 815–8. 12 Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98–110. Doi:10.1016/j.ccr.2009.12.020. 13 Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22: 425– 37. Doi:10.1016/j.ccr.2012.08.024. 14 Zheng S, Chheda MG, Verhaak RG. Studying a complex tumor: potential and pitfalls. Cancer J 2012; 18: 107–14. 15 Garnier D, Magnus N, D’Asti E, Hashemi M, Meehan B, Milsom C, Rak J. Genetic pathways linking hemostasis and cancer. Thromb Res 2012; 129(Suppl 1): S22–9. 16 Zhang Y, Zhan H, Xu W, Yuan Z, Lu P, Zhan L, Li Q. Upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 promotes the progression of human gliomas. Pathol Res Pract 2011; 207: 24–9. Doi:10.1016/j.prp.2010.10.003. 17 Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost 2004; 30: 31–44. 18 Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D, Ramirez L, Julian J. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012; 10: 807–14. Doi:10.1111/j.1538-7836.2012.04693.x.

[1]  J. Jespersen,et al.  Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal , 2013, Journal of thrombosis and haemostasis : JTH.

[2]  V. Haufroid,et al.  The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients , 2012, Pharmacogenetics and genomics.

[3]  W. Sadee,et al.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.

[4]  S. le Cessie,et al.  Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. , 2011, European heart journal.

[5]  A. Hofman,et al.  Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes , 2011, Pharmacogenetics and genomics.

[6]  Fernando Rivadeneira,et al.  A genome-wide association study of acenocoumarol maintenance dosage. , 2009, Human molecular genetics.

[7]  J. Corral,et al.  Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. , 2009, Blood.

[8]  L. Becquemont Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice , 2008, European Journal of Clinical Pharmacology.

[9]  I. Paskaleva,et al.  Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements , 2007, Journal of clinical pharmacy and therapeutics.